Chanut Franck J A, Sanvito Francesca, Ferrari Giuliana, Visigalli Ilaria, Carriglio Nicola, Hernandez Raisa Jofra, Norata Rossana, Doglioni Claudio, Naldini Luigi, Cristofori Patrizia
Formerly GSK David Jack Centre for R&D, Ware, United Kingdom, Currently SANOFI, Alfortville, France.
San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Hum Gene Ther. 2021 Jan;32(1-2):66-76. doi: 10.1089/hum.2020.135. Epub 2020 Oct 15.
Hematopoietic stem cell gene therapy has become a successful therapeutic strategy for some inherited genetic disorders. Pre-clinical toxicity studies performed to support the human clinical trials using viral-mediated gene transfer and autologous hematopoietic stem and progenitor cell (HSPC) transplantation are complex and the use of mouse models of human diseases makes interpretation of the results challenging. In addition, they rely on the use of conditioning agents that must induce enough myeloablation to allow engraftment of transduced and transplanted HSPC. Busulfan and total body irradiation (TBI) are the most commonly used conditioning regimens in the mouse. Lenticular degeneration and atrophy of reproductive organs are expected histopathological changes. Proliferative and nonproliferative lesions can be observed with different incidence and distribution across strains and mouse models of diseases. The occurrence of these lesions can interfere with the interpretation of pre-clinical toxicity and tumorigenicity studies performed to support the human clinical studies. As such, it is important to be aware of the background incidence of lesions induced by different conditioning regimens. We review the histopathology results from seven long-term studies, five using TBI and two using busulfan.
造血干细胞基因治疗已成为治疗某些遗传性疾病的成功策略。为支持使用病毒介导的基因转移和自体造血干细胞及祖细胞(HSPC)移植的人体临床试验而进行的临床前毒性研究很复杂,而且使用人类疾病的小鼠模型使得结果的解释具有挑战性。此外,这些研究依赖于使用预处理药物,这些药物必须诱导足够的骨髓消融,以允许转导和移植的HSPC植入。白消安和全身照射(TBI)是小鼠中最常用的预处理方案。晶状体变性和生殖器官萎缩是预期的组织病理学变化。在不同品系和疾病小鼠模型中,可以观察到增殖性和非增殖性病变,其发生率和分布各不相同。这些病变的出现可能会干扰为支持人体临床研究而进行的临床前毒性和致瘤性研究的解释。因此,了解不同预处理方案诱导的病变的背景发生率很重要。我们回顾了七项长期研究的组织病理学结果,其中五项使用TBI,两项使用白消安。